Jean-Paul Bahary

Jean-Paul Bahary

UNVERIFIED PROFILE

Are you Jean-Paul Bahary?   Register this Author

Register author
Jean-Paul Bahary

Jean-Paul Bahary

Publications by authors named "Jean-Paul Bahary"

Are you Jean-Paul Bahary?   Register this Author

55Publications

1759Reads

35Profile Views

Risk factors for biochemical recurrence after a tissue-ablative prostate-specific antigen <0.2 ng/mL.

Brachytherapy 2018 Sep - Oct;17(5):794-798. Epub 2018 Jun 29.

Department of Radiation Oncology, Centre Hospitalier de l'Université de Montréal, Hôpital Notre-Dame, Montréal, Canada; CRCHUM-Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brachy.2018.05.011DOI Listing
March 2019

A comparison of early prostate-specific antigen decline between prostate brachytherapy and different fractionation of external beam radiation-Impact on biochemical failure.

Brachytherapy 2018 Mar - Apr;17(2):277-282. Epub 2018 Jan 3.

Department of Radiation Oncology, Centre Hospitalier de l'Université de Montréal, Hôpital Notre-Dame, Montréal, Canada; CRCHUM-Centre de Recherche du Centre Hospitalier de l'Université de Montréal, Montreal, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brachy.2017.11.014DOI Listing
January 2019

Pre-radiotherapy PSA progression is a negative prognostic factor in prostate cancer patients using 5‑alpha-reductase inhibitors.

Strahlenther Onkol 2018 01 10;194(1):17-22. Epub 2017 Jul 10.

Department of Radiation Oncology, Centre hospitalier de l'Université de Montréal, Hôpital Notre-Dame, 1560 Sherbrooke St. E., H2L 4M1, Montréal, QC, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s00066-017-1176-zDOI Listing
January 2018

A Combination of Testosterone and White Blood Cell Count as a Predictive Factor of Overall Survival in Localized Prostate Cancer.

Target Oncol 2017 10;12(5):695-701

Department of Radiation Oncology, Centre Hospitalier de l'Université de Montréal - Hôpital Notre-Dame, 1560 Sherbrooke St. E., Montreal, QC, H2L 4M1, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11523-017-0516-3DOI Listing
October 2017

Randomized Trial of a Hypofractionated Radiation Regimen for the Treatment of Localized Prostate Cancer.

J Clin Oncol 2017 Jun 15;35(17):1884-1890. Epub 2017 Mar 15.

Charles N. Catton, Peter W.M. Chung, Patrick Cheung, Padraig Warde, and Tim K. Craig, University of Toronto, Toronto; Himu Lukka, Chu-Shu Gu, Theodoros Tsakiridis, Tom B. Corbett, Ian S. Dayes, Jim A. Julian, and Mark N. Levine, McMaster University, Hamilton; Glenn S. Bauman, University of Western Ontario, London, Ontario; Jean-Paul Bahary, University of Montreal, Montreal, Quebec; Shahida Ahmed, University of Manitoba, Winnipeg, Manitoba; Jackson S. Wu, University of Calgary, Calgary; Matthew B. Parliament, University of Alberta, Edmonton, Alberta, Canada; Jarad M. Martin, University of Newcastle, Newcastle, New South Wales; Keen Hun Tai, University of Melbourne, Melbourne, Victoria; Colin Tang, Sir Charles Gairdner Hospital, Nedlands, Western Australia, Australia; and Stéphane Supiot, University of Nantes, Nantes, France.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2016.71.7397DOI Listing
June 2017

Comparison of external beam radiotherapy versus permanent seed brachytherapy as monotherapy for intermediate-risk prostate cancer - a single center Canadian experience.

Can J Urol 2017 Jun;24(3):8822-8826

Department of Radiation Oncology, Centre Hospitalier de l'Université de Montréal, Hôpital Notre-Dame, Montréal, Québec, Canada.

View Article

Download full-text PDF

Source
June 2017

Radiation with or without Antiandrogen Therapy in Recurrent Prostate Cancer.

N Engl J Med 2017 02;376(5):417-428

From Massachusetts General Hospital and Harvard Medical School, Boston (W.U.S., N.M.H., A.L.Z.); NRG Oncology Statistics and Data Management Center (W.S., J.J.D., S.L.P.) and Einstein Medical Center (K.L.Z.), Philadelphia; Juravinski Cancer Centre at Hamilton Health Sciences, Hamilton, ON (H.R.L., P.P.M., M.P.P.), Hospital Notre-Dame du Centre Hospitalier de l'Université de Montréal (J.-P.B.) and McGill University Health Centre (L.S.), Montreal, and Tom Baker Cancer Centre, Calgary, AB (A.G.B.) - all in Canada; Indiana University, Indianapolis (D.J.G.); Tulane University, New Orleans (O.S.); Mayo Clinic, Rochester, MN (T.M.P.); Medical College of Wisconsin, Milwaukee (C.A.F.L.); University of Michigan, Ann Arbor (F.Y.F.); University of Vermont Medical Center, Burlington (R.D.L.); Radiation Oncology Center, Sacramento (S.A.R.), and Cedars-Sinai Medical Center, Los Angeles (H.M.S.) - both in California; Wayne Radiation Oncology, Goldsboro, NC (K.J.K.); and the University of Chicago, Chicago (J.J.D.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1607529DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5444881PMC
February 2017

Radiation plus Procarbazine, CCNU, and Vincristine in Low-Grade Glioma.

N Engl J Med 2016 Apr;374(14):1344-55

From the Mayo Clinic, Rochester, MN (J.C.B.); Wake Forest University School of Medicine, Winston-Salem (E.G.S.), and Triangle Neurosurgeons, Raleigh (D. Bullard) - both in North Carolina; NRG Oncology Statistics and Data Management Center, Philadelphia (S.L.P., M.W.); Ohio State University, Columbus (A.C., E.H.B.), and Cleveland Clinic, Cleveland (J.H.S.) - both in Ohio; M.D. Anderson Cancer Center, University of Texas, Houston (M.R.G., P.D.B.); Wayne State University, Detroit (G.R.B., H.K.); Barrow Neurological Institute (S.C.) and Arizona Oncology Services Foundation (D. Brachman) - both in Phoenix; Radiology Imaging Associates, Englewood, CO (P.R.); Mid-Columbia Medical Center, The Dalles, OR (K.S.); Medical College of Wisconsin, Milwaukee (C.J.S.); Centre Hospitalier de l'Université de Montréal, Montreal (J.-P.B.), the London Regional Cancer Program, London, ON (B.J.F.), and the Cross Cancer Institute, Edmonton, AB (A.D.M.) - all in Canada; University of Maryland, Baltimore (M.P.M.); and Emory University, Atlanta (W.J.C.).

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1056/NEJMoa1500925DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC5170873PMC
April 2016

Impact of Radiotherapy When Added to Androgen-Deprivation Therapy for Locally Advanced Prostate Cancer: Long-Term Quality-of-Life Outcomes From the NCIC CTG PR3/MRC PR07 Randomized Trial.

J Clin Oncol 2015 Jul 26;33(19):2151-7. Epub 2015 May 26.

Michael Brundage, Queen's Cancer Research Institute and Cancer Centre of Southeastern Ontario; Wendy R. Parulekar and Bingshu E. Chen, NCIC Clinical Trials Group, Queen's University, Kingston; Padraig Warde and Andrea Bezjak, Princess Margaret Cancer Center, Toronto, Ontario; Matthew Parliament, Cross Cancer Institute, Edmonton, Alberta; Jean-Paul Bahary, Centre Hospitalier de l'Université de Montréal-Hôpital Notre-Dame, Montreal, Quebec, Canada; Matthew R. Sydes, Mahesh K.B. Parmar, and Karen Sanders, Medical Research Council Clinical Trials Unit, University College London, London; Richard Cowan, Christie Hospital and University of Manchester, Manchester; Peter Kirkbride, Clatterbridge Cancer Centre, National Health Service Foundation Trust, Wirral; Clare Moynihan, Institute of Cancer Research, Sutton; and Malcolm D. Mason, Cardiff University School of Medicine, Velindre Hospital, Cardiff, United Kingdom.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1200/JCO.2014.57.8724DOI Listing
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4477787PMC
July 2015

The Cancer of the Prostate Risk Assessment (CAPRA) score predicts biochemical recurrence in intermediate-risk prostate cancer treated with external beam radiotherapy (EBRT) dose escalation or low-dose rate (LDR) brachytherapy.

BJU Int 2014 Dec 14;114(6):865-71. Epub 2014 Mar 14.

Departement of Radiation Oncology, Centre Hospitalier de l'Université de Montréal (CHUM), Hôpital Notre-Dame, Montreal, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1111/bju.12587DOI Listing
December 2014

Analysis of the Cancer of the Prostate Risk Assessment to predict for biochemical failure after external beam radiotherapy or prostate seed brachytherapy.

Urology 2014 Sep;84(3):629-33

Department of Radiation Oncology, Hôpital Notre-Dame, Center Hospitalier de l'Université de Montréal (CHUM), Montreal, Canada; University of Montreal Hospital Research Centre, Montreal, Canada. Electronic address:

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2014.05.032DOI Listing
September 2014

A criterion-based audit of the technical quality of external beam radiotherapy for prostate cancer.

Radiother Oncol 2013 Jun 2;107(3):339-45. Epub 2013 Jul 2.

Division of Cancer Care and Epidemiology, Queen's Cancer Research Institute, Kingston, Ontario, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.radonc.2013.04.023DOI Listing
June 2013

Long-term results of radiosurgery for cerebral arteriovenous malformations.

Can J Neurol Sci 2013 Mar;40(2):182-6

Radiation Oncology Department, McGill University Health Center, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1017/s0317167100013706DOI Listing
March 2013

Effect of statins and anticoagulants on prostate cancer aggressiveness.

Int J Radiat Oncol Biol Phys 2012 Jul 21;83(4):1149-53. Epub 2012 Jan 21.

Department of Radiation Oncology, Centre Hospitalier de l'Université de Montréal, Montreal, Quebec, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2011.09.042DOI Listing
July 2012

Hypofractionated radiotherapy in prostate cancer.

Expert Rev Anticancer Ther 2012 Jul;12(7):965-72

Department of Radiation Oncology, Hôpital Maisonneuve-Rosemont, 5415 Boulevard de l'Assomption, Montréal, QC H1T 2M4, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1586/era.12.70DOI Listing
July 2012

The importance of an exponential prostate-specific antigen decline after external beam radiotherapy for intermediate risk prostate cancer.

Cancer Epidemiol 2012 Apr 16;36(2):e137-41. Epub 2011 Nov 16.

Department of Radiation Oncology, Centre hospitalier de l'Université de Montréal, Québec, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.canep.2011.10.007DOI Listing
April 2012

Development of indicators of the quality of radiotherapy for localized prostate cancer.

Radiother Oncol 2011 Apr 30;99(1):29-36. Epub 2011 Mar 30.

Department of Oncology, University of Alberta, Edmonton, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.radonc.2011.02.013DOI Listing
April 2011

Comparison between high and low source activity seeds for I-125 permanent seed prostate brachytherapy.

Int J Radiat Oncol Biol Phys 2010 Nov 19;78(3):781-6. Epub 2010 Feb 19.

Department of Radiation Oncology, Centre Hospitalier de l'Université de Montréal, Montreal, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2009.08.057DOI Listing
November 2010

Association between erectile function and lower urinary tract symptoms in patients treated with permanent seed prostate brachytherapy.

Can J Urol 2010 Aug;17(4):5259-64

Department of Radiation Oncology, University of Montreal Medical Centre (CHUM), Montreal, Quebec, Canada.

View Article

Download full-text PDF

Source
August 2010

Factors influencing treatment decisions in patients with low risk prostate cancer referred to a brachytherapy clinic.

Can J Urol 2008 Dec;15(6):4415-20

Department of Radiation, University of Montreal Medical Center (CHUM), Montreal, Quebec, Canada.

View Article

Download full-text PDF

Source
December 2008

Does timing of androgen deprivation influence radiation-induced toxicity? A secondary analysis of radiation therapy oncology group protocol 9413.

Urology 2008 Nov 7;72(5):1125-9. Epub 2008 Mar 7.

Department of Radiation Oncology, Montreal University, Montreal, Quebec, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.urology.2007.11.067DOI Listing
November 2008

Poor predictive value of intraoperative real-time dosimetry for prostate seed brachytherapy.

Int J Radiat Oncol Biol Phys 2008 Oct;72(2):605-9

Département de Radio-Oncologie, CHUM - Hôpital Notre-Dame, Montreal, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2008.06.1484DOI Listing
October 2008

Combined hypofractionated radiation and hormone therapy for the treatment of intermediate-risk prostate cancer.

Int J Radiat Oncol Biol Phys 2008 May;71(1):58-63

Department of Radiation Oncology, University of Montreal, CHUM - Notre-Dame Hospital, Montreal, Quebec, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.ijrobp.2007.09.004DOI Listing
May 2008

Higher frequency of familial clustering of prostate cancer in French-Canadian men.

J Urol 2007 Oct 14;178(4 Pt 1):1265-9; discussion 1270. Epub 2007 Aug 14.

Département de Radio-Oncologie, Centre Hospitalier Université de Montréal, Montréal, Québec, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.juro.2007.05.131DOI Listing
October 2007

Combined low dose ionizing radiation and green tea-derived epigallocatechin-3-gallate treatment induces human brain endothelial cells death.

J Neurooncol 2006 Nov 19;80(2):111-21. Epub 2006 May 19.

Laboratoire de Médecine Moléculaire, Centre de Cancérologie Charles-Bruneau, Hôpital Sainte-Justine-UQAM, Montréal, Québec, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1007/s11060-006-9171-8DOI Listing
November 2006

The response to brain tumor-derived growth factors is altered in radioresistant human brain endothelial cells.

Cancer Biol Ther 2006 Nov 30;5(11):1539-45. Epub 2006 Nov 30.

Laboratoire de Médecine Moléculaire, Centre de Cancérologie Charles-Bruneau, Hôpital Sainte-Justine-UQAM, Montreal, Quebec, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.4161/cbt.5.11.3459DOI Listing
November 2006

The Survivin-mediated radioresistant phenotype of glioblastomas is regulated by RhoA and inhibited by the green tea polyphenol (-)-epigallocatechin-3-gallate.

Brain Res 2006 Feb 10;1071(1):1-9. Epub 2006 Jan 10.

Laboratoire de Médecine Moléculaire, Centre de Cancérologie Charles-Bruneau, Hôpital Sainte-Justine-UQAM, Québec, Canada.

View Article

Download full-text PDF

Source
http://dx.doi.org/10.1016/j.brainres.2005.10.009DOI Listing
February 2006

Radiation induced-tubulogenesis in endothelial cells is antagonized by the antiangiogenic properties of green tea polyphenol (-) epigallocatechin-3-gallate.

Cancer Biol Ther 2003 Nov-Dec;2(6):642-9

Laboratoire de Médecine Moléculaire, Centre de Cancérologie Charles-Bruneau, Hôpital Sainte-Justine and Université du Québec a Montreal, Montreal, Quebec, Canada.

View Article

Download full-text PDF

Source
September 2004

Endovascular treatment of intracranial aneurysms with radioactive coils: initial clinical experience.

Stroke 2003 Dec 6;34(12):2801-6. Epub 2003 Nov 6.

Department of Radiology, Centre hospitalier de l'Université de Montréal (CHUM)-Notre Dame Hospital, Montreal, Quebec, Canada.

View Article

Download full-text PDF

Source
https://www.ahajournals.org/doi/10.1161/01.STR.0000098651.14
Publisher Site
http://dx.doi.org/10.1161/01.STR.0000098651.14384.ABDOI Listing
December 2003